Cargando…

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab

Detalles Bibliográficos
Autores principales:	Khunger, Monica, Velcheti, Vamsidhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Association for the Study of Lung Cancer. Published by Elsevier Inc. 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128997/ https://www.ncbi.nlm.nih.gov/pubmed/28629548 http://dx.doi.org/10.1016/j.jtho.2017.03.008

Ejemplares similares

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
por: Khunger, Arjun, et al.
Publicado: (2018)

Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
por: Khunger, Monica, et al.
Publicado: (2018)

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis
por: Ide, Maako, et al.
Publicado: (2018)

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017)

Primary squamous cell carcinoma of the pleura treated with nivolumab
por: Sigala, Ioanna, et al.
Publicado: (2020)

Case series of pleomorphic carcinomas of the lung treated with nivolumab
por: Kanazu, Masaki, et al.
Publicado: (2017)

Role of immune-checkpoint inhibitors in lung cancer
por: Jain, Prantesh, et al.
Publicado: (2018)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?
por: Sehgal, Sameep, et al.
Publicado: (2016)

Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma
por: Ding, Ling, et al.
Publicado: (2016)

Lung Transplantation in Idiopathic Pulmonary Fibrosis
por: Laporta Hernandez, Rosalía, et al.
Publicado: (2018)

Lung Transplantation for Idiopathic Pulmonary Fibrosis
por: Lamas, Daniela J., et al.
Publicado: (2013)

Physiology of the lung in idiopathic pulmonary fibrosis
por: Plantier, Laurent, et al.
Publicado: (2018)

Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report
por: Chen, Yu-Hsiu, et al.
Publicado: (2017)

Idiopathic pulmonary fibrosis diagnosed concomitantly with diffuse squamous cell lung cancer on surgical lung biopsy: a case report
por: Niel, C., et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis with bronchogenic carcinoma
por: Nair, Girija, et al.
Publicado: (2009)

Nintedanib—A case of treating concurrent idiopathic pulmonary fibrosis and non‐small cell lung cancer
por: Dabholkar, Shakti, et al.
Publicado: (2022)

Regression of Lung Squamous Cell Carcinoma after the Withdrawal of Cyclosporin A Combined with Pirfenidone Treatment in a Patient with Idiopathic Pulmonary Fibrosis
por: Takahashi, Mari, et al.
Publicado: (2020)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)

Autophagy in Idiopathic Pulmonary Fibrosis: Predisposition of the Aging Lung to Fibrosis?
por: Zmijewski, Jaroslaw W., et al.
Publicado: (2022)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges
por: Abu Qubo, Ahmad, et al.
Publicado: (2022)

Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis
por: Wang, Xiao Mei, et al.
Publicado: (2006)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma
por: Kishi, Seiji, et al.
Publicado: (2017)

The reliability of lung ultrasound in assessment of idiopathic pulmonary fibrosis
por: Manolescu, Diana, et al.
Publicado: (2018)

Alterations to the Lung Microbiome in Idiopathic Pulmonary Fibrosis Patients
por: Tong, Xunliang, et al.
Publicado: (2019)

Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
por: Balestro, Elisabetta, et al.
Publicado: (2019)

Lung function trajectories in patients with idiopathic pulmonary fibrosis
por: Neely, Megan L, et al.
Publicado: (2023)

Invadosome Formation by Lung Fibroblasts in Idiopathic Pulmonary Fibrosis
por: Lebel, Mégane, et al.
Publicado: (2022)

A model of the aged lung epithelium in idiopathic pulmonary fibrosis
por: Shaghaghi, Hoora, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

Antifibrotic therapy in idiopathic pulmonary fibrosis candidates for lung transplantation undergoing pulmonary rehabilitation
por: Pereira, Monica Pruss, et al.
Publicado: (2023)

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
por: Ren, Hui, et al.
Publicado: (2017)

High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas
por: Velcheti, Vamsidhar, et al.
Publicado: (2013)

Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report
por: Fujimoto, Eriko, et al.
Publicado: (2018)

Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?
por: Ruaro, Barbara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0dmtiq15lhhh2ue0uoiruhej3t